Evidence map›Paper›PMID 22737224›Full record

ArticlePloS one2012

Isolation of monoclonal antibodies with predetermined conformational epitope specificity.

Anton M Sholukh, Muhammad M Mukhtar, Michael Humbert, Sosthène S Essono, Jennifer D Watkins, Hemant K Vyas, Vivekanandan Shanmuganathan, Girish Hemashettar, Maria Kahn, Shiu-Lok Hu and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Anton M SholukhDepartment of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
Muhammad M Mukhtar
Michael Humbert
Sosthène S Essono
Jennifer D Watkins
Hemant K Vyas
Vivekanandan Shanmuganathan
Girish Hemashettar
Maria Kahn
Shiu-Lok Hu
David C Montefiori
Victoria R Polonis
Peter H Schur
Ruth M Ruprecht
Harvard University · USDana-Farber Cancer Institute · USUniversity of Washington · USDuke University · USWalter Reed Army Institute of Research · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Virology and ImmunologyP01AI048240 · NIAID · UNIVERSITY OF WASHINGTON · PI RUPRECHT, RUTH MARGRIT · 2000 to 2020
$46.7M
Infant Immunoprophylaxis against a Primate LentivirusR37AI034266 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI RUPRECHT, RUTH MARGRIT · 2003 to 2012
$7.7M
Correlates of protection against SIV/SHIV challengeP01AI082282 · NIAID · WISTAR INSTITUTE · PI ERTL, HILDEGUND C. J. · 2009 to 2010
$5.6M
NIAID NIH HHS P01 AI048240NIAID NIH HHS P01 AI048240-08S1NIAID NIH HHS P01 AI082282NIAID NIH HHS P30 AI060354NIAID NIH HHS R37 AI034266
6 · The paper itself

Abstract

Existing technologies allow isolating antigen-specific monoclonal antibodies (mAbs) from B cells. We devised a direct approach to isolate mAbs with predetermined conformational epitope specificity, using epitope mimetics (mimotopes) that reflect the three-dimensional structure of given antigen subdomains. We performed differential biopanning using bacteriophages encoding random peptide libraries and polyclonal antibodies (Abs) that had been affinity-purified with either native or denatured antigen. This strategy yielded conformational mimotopes. We then generated mimotope-fluorescent protein fusions, which were used as baits to isolate single memory B cells from rhesus monkeys (RMs). To amplify RM immunoglobulin variable regions, we developed RM-specific PCR primers and generated chimeric simian-human mAbs with predicted epitope specificity. We established proof-of-concept of our strategy by isolating mAbs targeting the conformational V3 loop crown of HIV Env; the new mAbs cross-neutralized viruses of different clades. The novel technology allows isolating mAbs from RMs or other hosts given experimental immunogens or infectious agents.

Indexed as

AnimalsAntibodies, MonoclonalAutoantigensBacteriophagesB-LymphocytesCell Line, TumorCell Separationenv Gene Products, Human Immunodeficiency VirusEpitope MappingEpitopesFlow CytometryHIVHumansImmunologic TechniquesLeukocytes, MononuclearPeptide LibraryAntibodies, MonoclonalAutoantigensenv Gene Products, Human Immunodeficiency VirusEpitopesPeptide LibraryPeptides

Identifiers

PMID22737224
PMCPMC3380854
OpenAlexW2049956343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.